MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Heat Biologics Company Profile (NASDAQ:HTBX)

Consensus Ratings for Heat Biologics (NASDAQ:HTBX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.44 (1,651.76% upside)

Analysts' Ratings History for Heat Biologics (NASDAQ:HTBX)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Roth CapitalInitiated CoverageBuy$2.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/21/2016HC WainwrightReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Noble FinancialReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Heat Biologics (NASDAQ:HTBX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/11/2016Q1($0.56)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q4($0.64)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2015Q3($0.61)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.47)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q1($0.49)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/16/2015($0.49)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2015($0.44)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.42)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.40)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.38)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/1/2014($0.30)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Heat Biologics (NASDAQ:HTBX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Heat Biologics (NASDAQ:HTBX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Heat Biologics (NASDAQ:HTBX)
DateHeadline
06/22/16 04:38 PMHeat Biologics, Inc. (HTBX) Current Analyst Ratings - Fiscal Standard
06/20/16 06:49 AMCoverage initiated on Heat Biologics by ROTH Capital -
06/17/16 04:25 PMRecently Issued Stock Ratings For Heat Biologics, Inc. (HTBX) - Fiscal Standard
06/06/16 06:18 AMHeat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting - [at noodls] - Poster reviews trial design and endpoints Additional data illustrates clinical and immune response correlation DURHAM, N.C., June 06, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), an immuno-oncology ...
06/02/16 04:46 PMStrong Sell Calls Count For Heat Biologics, Inc. (NASDAQ:HTBX) At 0 - Investor Newswire - Strong Sell Calls Count For Heat Biologics, Inc. (NASDAQ:HTBX) At 0Investor NewswireThe Sell calls on Heat Biologics, Inc. (NASDAQ:HTBX) were 0. Two months earlier 1 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 0. The buy recommendations were 0 and sell calls count was 0. Analyst ...and more »
06/02/16 07:17 AMBroker Watchlist: Heat Biologics, Inc. (HTBX) - Share Trading News - Broker Watchlist: Heat Biologics, Inc. (HTBX)Share Trading News05/18/2015 – Heat Biologics, Inc. was upgraded to “hold” by analysts at Zacks. The share price of Heat Biologics, Inc. (HTBX) was down -3.90% during the last trading session, with a day high of 0.72. 699487 shares were traded on Heat Biologics, Inc.'s ...
05/31/16 08:05 AMObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ... - Is stories - Is storiesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesIn most recently trading session on 5/27/2016, Heat Biologics, Inc. (NASDAQ:HTBX) climbed +5.4961% while traded on 1.1 million shares versus it's an average volume of 661.47 thousand shares. The company recorded the last trade with the price of ...and more »
05/28/16 12:37 PMHeat Biologics, Inc. (HTBX) Updated Broker Price Targets - Share Trading News - Heat Biologics, Inc. (HTBX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Heat Biologics, Inc. (HTBX). The latest reports which are currently in issue on Friday 27th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
05/26/16 12:40 PMNotable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Heat Biologics, Inc. (NASDAQ:HTBX) - Street Updates - Notable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Heat Biologics, Inc. (NASDAQ:HTBX)Street UpdatesHeat Biologics, Inc. (NASDAQ:HTBX) moved in green zone with rise of +0.02 points or +3.45% to $0.60. The company has a market worth of $10.51M.Total 352.12 thousand shares were exchanged in last trading session as opposed to average volume of ...and more »
05/11/16 06:02 AMHeat Biologics Reports First Quarter 2016 Financial Results - [at noodls] - DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/26/16 06:06 AMHeat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co. - [at noodls] - DURHAM, N.C., April 26, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/25/16 06:54 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
04/25/16 06:15 AMHeat Biologics Appoints Dr. John Prendergast to Board of Directors - [at noodls] - DURHAM, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, ...
04/09/16 02:01 PMBroker Changes For Heat Biologics, Inc. (HTBX) - Risers & Fallers - NYSE Journal (press release)Broker Changes For Heat Biologics, Inc. (HTBX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Heat Biologics, Inc. (HTBX). The latest broker reports which are currently outstanding on Friday 8th of April state 0 analysts have a rating of “strong buy”, 3 analysts ...Heat Biologics (HTBX) Announces Cost Cuts; Will Reduce Workforce by ~22%StreetInsider.comHeat Biologics, Inc. (NASDAQ:HTBX) Declined More Than 2 Percent TodayNYSE Journal (press release)Heat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Increased By 196.63%SmallCapWired.comSonoran Weekly Review -Franklin Independentall 12 news articles »
04/09/16 02:01 PMAnalysts Actions to Focus: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Heat Biologics, Inc. (NASDAQ:HTBX) - Street Updates - Analysts Actions to Focus: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Heat Biologics, Inc. (NASDAQ:HTBX)Street UpdatesIn the past trading session, Heat Biologics, Inc. (NASDAQ:HTBX) highlighted downward shift of -9.6536% or -0.0641 points to $0.5999. The company traded a volume of 1.26 million shares over average volume of 420.85 thousand shares. Trailing twelve ...and more »
04/07/16 12:44 PMDurham's Heat Bio to lay off 22% of workforce, reduce trial enrollment -
04/07/16 06:12 AMHeat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones - [at noodls] - Cost-saving measures enable Heat to achieve Phase 2 HS-410 bladder cancer data readout in 4Q:16 with its current cash on-hand DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') ...
04/07/16 06:11 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with Exit or Di -
03/09/16 06:00 AMHeat Biologics’ CSO to Participate in the 27th Annual Cancer Progress Conference by Defined Health - [GlobeNewswire] - DURHAM, N.C., March 09, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that Taylor Schreiber, M.D., ...
03/07/16 03:05 PMHeat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia - [GlobeNewswire] - DURHAM, N.C., March 07, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that positive preclinical data ...
03/04/16 06:00 AMHeat Biologics to Present at the 28th Annual ROTH Conference - [GlobeNewswire] - DURHAM, N.C., March 04, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that the company is scheduled ...
03/03/16 04:02 PMHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit -
02/26/16 08:53 AMReasons to Watch: Heat Biologics, Inc. - Heat Biologics, Inc. (NASDAQ:HTBX) caters to the Healthcare space. Its weekly performance is -24.15%. On the last day of trading company shares ended up at $1.57. Heat Biologics, Inc. (NASDAQ:HTBX) distance from 50-day simple moving average (SMA50 ...
02/26/16 08:53 AMHeat Biologics (HTBX) Ceases Enrollment in HS-410 Phase 2; Shortage No Longer Reported - Heat Biologics, Inc. (Nasdaq: HTBX) announced that the company will no longer enroll new patients in its Phase 2 monotherapy trial arm evaluating HS-410 alone for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat added the monotherapy trial ...
02/25/16 06:11 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
02/25/16 06:00 AMHeat Biologics Provides Update on Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm - [GlobeNewswire] - No longer enrolling new patients in monotherapy trial arm due to the current availability of standard of care BCG No safety concerns related to HS-410; all enrolled patients receiving HS-410 will continue ...
02/23/16 10:20 AMHeat Biologics faces a delisting from Nasdaq -
02/23/16 07:46 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa -
02/19/16 08:45 AMDurham drug developer to raise cash, but dilute shareholders' stake -
02/18/16 06:13 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -
02/18/16 06:00 AMHeat Biologics Reports Fiscal Year 2015 Financial Results - [GlobeNewswire] - DURHAM, N.C., Feb. 18, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, reported financial results for the fiscal ...
02/15/16 12:14 PMHeat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Increased By 37.81% - fdanewsalert.com - Heat Biologics Incorporated (NASDAQ:HTBX) Shorted Shares Increased By 37.81%fdanewsalert.comThe short interest to Heat Biologics Incorporated's float is 1.77%. The stock decreased 0.70% or $0.01 on February 12, hitting $2.13. About 26,651 shares traded hands. Heat Biologics Inc (NASDAQ:HTBX) has declined 66.46% since July 10, 2015 and is ...
02/15/16 12:14 PMHeat Biologics, Inc. (HTBX) Recent Analyst Updates - Risers & Fallers - Heat Biologics, Inc. (HTBX) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Heat Biologics, Inc. (HTBX). According to the latest broker reports outstanding on Monday 15th of February, 1 analyst has a rating of “strong buy”, 2 analysts “buy”, ...
02/13/16 12:41 PMThe FDA Lifts The Partial Clinical Hold For Heat Biologics Inc (NASDAQ:HTBX) - fdanewsalert.com - The FDA Lifts The Partial Clinical Hold For Heat Biologics Inc (NASDAQ:HTBX)fdanewsalert.comHeat Biologics Inc, (NASDAQ:HTBX) breathed a sigh of relief after the lifting of the partial clinical hold on the company's phase II trial evaluation of its lead pipeline candidate, HS-410 (vesigenurtacel-L) by the U.S. Food and Drug Administration ...Heat Biologics' (HTBX) "Buy" Rating Reaffirmed at Noble FinancialThe Vista Voiceall 2 news articles »
02/11/16 03:30 PMHeat Biologics Up as FDA Lifts Partial Hold on Phase II Study -
02/11/16 12:39 PMLift of Partial Clinical Hold on Heat Biologics' (HTBX) HS-410 Much Earlier than Expected; Noble Reaffirms at 'Buy' - StreetInsider.com - Lift of Partial Clinical Hold on Heat Biologics' (HTBX) HS-410 Much Earlier than Expected; Noble Reaffirms at 'Buy'StreetInsider.comNoble Financial affirms Heat Biologics, Inc. (Nasdaq: HTBX) at Buy with a price target of $16 after the company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's Phase 2 clinical trial ...
02/11/16 12:39 PMBig News Gains: ArcBest Corporation (NASDAQ:ARCB), Heat Biologics (NASDAQ:HTBX), Forward Pharma A/S (NASDAQ:FWP), Agenus (NASDAQ:AGEN) - On 10 February, Heat Biologics, Inc. (NASDAQ:HTBX) shares advanced 7.28% and was closed at $2.21. Heat Biologics, Inc. (NASDAQ:HTBX) year to date (YTD) performance is -9.43%. Heat Biologics, Inc. (NASDAQ:HTBX) announced that the U.S. Food and Drug ...
02/11/16 12:39 PMHeat Biologics (HTBX) Announces FDA Lifts Partial Clinical Hold on Phase 2 Trial Evaluating HS-410 - Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical ...
02/10/16 12:44 PMHeat Biologics (HTBX) Announces FDA Lifts Partial Clinical Hold on Phase 2 Trial Evaluating HS-410 - StreetInsider.com - Triangle Business JournalHeat Biologics (HTBX) Announces FDA Lifts Partial Clinical Hold on Phase 2 Trial Evaluating HS-410StreetInsider.comHeat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold ...Heat Biologics Incorporated (NASDAQ:HTBX) Short Interest Increased By 75.93%fdanewsalert.comFDA Lifts Heat Biologics Partial Clinical HoldGlobeNewswire (press release)Heat Biologics Inc (HTBX) Rating Increased to Hold at Zacks Investment ResearchDaily PoliticalStreet Editionall 13 news articles »
02/10/16 06:00 AMFDA Lifts Heat Biologics Partial Clinical Hold - [GlobeNewswire] - DURHAM, N.C., Feb. 10, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that the U.S. Food and Drug ...
02/09/16 04:00 PMThe fate of Heat Biologics, BioCryst could lie in the coming weeks -
02/03/16 10:35 AMFDA places 'partial hold' on drug trial by Durham's Heat Biologics; stocks drop -
02/03/16 06:00 AMHeat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial - [GlobeNewswire] - The company anticipates clinical timelines for HS-410 to remain materially unchanged DURHAM, N.C., Feb. 03, 2016-- Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate ...
01/26/16 11:32 AMLatest Analysts Reports On Heat Biologics, Inc. (HTBX) - Risers & Fallers - Latest Analysts Reports On Heat Biologics, Inc. (HTBX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Heat Biologics, Inc. (HTBX). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 ...Heat Biologics Inc (HTBX) Lifted to "Hold" at Zacks Investment ResearchCorvus Business NewswireHeat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder ...Nasdaqall 5 news articles »
01/26/16 11:32 AMHeat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase - DURHAM, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D. Ph.D., Heat's ...
01/26/16 06:19 AMHeat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference - [at noodls] - Early results support mechanism of action Six out of seven patients who have reached the 3-month timepoint remain recurrence free DURHAM, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ('Heat') ...
01/26/16 06:02 AM7:02 am Heat Biologics reports that to-date HS-410 has been well-tolerated, with no serious adverse events; anticipates reporting topline efficacy, immune-response and safety data from Phase 2 trials in 4Q16 -
01/25/16 10:43 AMCompany Shares of Heat Biologics, Inc. (NASDAQ:HTBX) Rally 2.39% - The Daily Rover - Company Shares of Heat Biologics, Inc. (NASDAQ:HTBX) Rally 2.39%The Daily RoverShares of Heat Biologics, Inc. (NASDAQ:HTBX) appreciated by 2.39% during the past week but lost 1.91% on a 4-week basis. In the past week, the shares have outperformed the S&P 500 by 0.96% and the outperformance increases to 6.02% for the last 4 ...
11/09/15 05:05 AMHEAT BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
11/06/15 06:14 AMHeat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - [at noodls] - HS-410 had a positive safety profile and was well-tolerated Unprecedented increase in intratumoral CD8+ T cells following vaccination DURHAM, N.C., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ...
About Heat Biologics

Heat Biologics logoHeat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patient's own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HTBX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.80
  • 50 Day Moving Average: $0.60
  • 200 Day Moving Average: $1.32
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $12.44M
  • Current Quarter EPS Consensus Estimate: $-1.11 EPS
Additional Links:
Heat Biologics (NASDAQ:HTBX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha